App-Quantinova.ai

A national, retrospective, observational study on the use of 5-aminosalicylates (5-ASA) in Crohn’s disease (CD)

A Hart - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Mesalamine

Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study

J R White - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series

J Lisle - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial

S Danese - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis

S Danese - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Budesonide

Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on adalimumab

D Yerlioglu - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Adalimumab

Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis

I Steenstraten - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary sclerosing cholangitis

N/A

Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland

A Eberl - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics

R Ranjan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Ferric carboxymaltose

Prospective study to predict psychological morbidity in young people with inflammatory bowel disease using novel risk assessment tool

A Hoogkamer - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Inflammatory bowel disease

N/A

Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

E V Loftus Jr - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Crohn's disease

ABT-494

Outcomes for patients with severe acute ulcerative colitis

M Shivakumar - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC

S Ghosh - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

The benefits of anti-TNF drug and antidrug antibody (ADAb) level monitoring in a DGH

C Matthews - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study

B Bressler - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Entyvio

The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease

R Ranjan - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Allmercap

Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial

J Ellis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriasis

GSK 2831781

Anti-mycobacterium paratuberculous therapy in Crohn’s disease: outcomes from tertiary IBD referral centres

E Johnston - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Biaxin

Diagnostic accuracy and usability of home calprotectin testing

A Thomas - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts